Beta Thalassemia Treatment Market Size & Share, by Therapy (Blood Transfusion, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, Bone Marrow Transplant); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5273
  • Published Date: Sep 28, 2023
  • Report Format: PDF, PPT

Companies Dominating the Beta Thalassemia Treatment Market

top-features-companies
    • Bluebird Bio Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Acceleron Pharma, Inc.
    • Celgene Corporation
    • GlaxoSmithKline plc
    • Incyte Corporation
    • Gamida Cell
    • Kiadis Pharma
    • La Jolla Pharmaceutical Company
    • Vertix Pharmaceuticals Incorporated
    • ApoPharma Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Zynteglo, a new generation of gene therapy for adult and paediatric patients with beta thalassemia that requires regular red cell transfusions, has been authorised by the US Food and Drug Administration.
  • CRISPR and Vertex Pharmaceuticals Incorporated announced the Fast Track Designation for CTX001 to treat transfusiondependent beta thalassemia has been given by the United States Food and Drug Administration. CTX001 is an investigational autologous, gene edited therapy of hematopoietic stem cells for patients with severe hemoglobinopathies.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5273
  • Published Date: Sep 28, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of beta thalassemia and increasing healthcare expenditure are some of the major factors anticipated to drive the growth of the cell culture consumables market.

The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2024 – 2036.

The major players in the market are of Celgene Corporation, GlaxoSmithKline plc, Incyte Corporation, Gamida Cell, Kiadis Pharma, La Jolla Pharmaceutical Company, Vertix Pharmaceuticals Incorporated, and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying